Edition:
United States

Inovio Pharmaceuticals Inc (INO.OQ)

INO.OQ on NASDAQ Stock Exchange Global Select Market

4.85USD
22 May 2018
Change (% chg)

$0.04 (+0.83%)
Prev Close
$4.81
Open
$4.81
Day's High
$4.85
Day's Low
$4.80
Volume
11,777
Avg. Vol
249,120
52-wk High
$9.85
52-wk Low
$3.77

Select another date:

Mon, May 21 2018

BRIEF-Inovio Opens Trial To Test Its VGX-3100 Drug In HPV Patients

* INOVIO OPENS PHASE 2 TRIAL FOR VGX-3100 IN THIRD INDICATION TO TREAT HPV – THE NO. 1 SEXUALLY TRANSMITTED DISEASE

BRIEF-Inovio Says HIV Vaccine Maintained Immune Responses One Year After Start Of Trial

* INOVIO HIV VACCINE, WHICH GENERATED NEAR 100% IMMUNE RESPONSES, SUSTAINED DURABLE MEMORY RESPONSES MEASURED ONE YEAR AFTER THE START OF CLINICAL TRIAL Source text for Eikon: Further company coverage:

BRIEF-Inovio Pharmaceuticals Q1 Loss Per Share $0.36

* INOVIO PHARMACEUTICALS REPORTS 2018 FIRST QUARTER FINANCIAL RESULTS

BRIEF-Inovio Pharmaceuticals Says For Qtr Ended March 31, Net Loss Per Share Was $0.36

* INOVIO PHARMACEUTICALS SAYS FOR THREE MONTHS ENDED MARCH 31, 2018, NET LOSS PER SHARE WAS $0.36 - SEC FILING

BRIEF-Inovio Awarded Up To $56 Million From Cepi To Advance Dna Vaccines Against Lassa Fever And Mers

* INOVIO AWARDED UP TO $56 MILLION FROM CEPI TO ADVANCE DNA VACCINES AGAINST LASSA FEVER AND MERS

BRIEF-Inovio Closes License And Collaboration Agreement With ApolloBio To Develop And Commercialize VGX-3100 In Greater China

* INOVIO CLOSES LICENSE AND COLLABORATION AGREEMENT WITH APOLLOBIO TO DEVELOP AND COMMERCIALIZE VGX-3100 IN GREATER CHINA

BRIEF-Inovio Pharmaceuticals Reports Qtrly ‍Net Loss Attributable To Stockholders Of $0.24 Per Basic Share​

* INOVIO PHARMACEUTICALS REPORTS 2017 FOURTH QUARTER AND YEAR END FINANCIAL RESULTS

BRIEF-Inovio's DNA Immunotherapy Demonstrates Immune Response Results Key In Treating Chronic Hepatitis B Infection

* INOVIO'S DNA IMMUNOTHERAPY DEMONSTRATES IMMUNE RESPONSE RESULTS KEY IN TREATING CHRONIC HEPATITIS B INFECTION Source text for Eikon: Further company coverage:

BRIEF-Inovio Pharmaceuticals, Parker Institute For Cancer Immunotherapy Establish Clinical Development Collaboration To Evaluate Novel Cancer Immunotherapy Combinations

* INOVIO PHARMACEUTICALS AND THE PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY ESTABLISH CLINICAL DEVELOPMENT COLLABORATION TO EVALUATE NOVEL CANCER IMMUNOTHERAPY COMBINATIONS

BRIEF-Inovio Receives Milestone Payment From Medimmune

* INOVIO RECEIVES MILESTONE PAYMENT FROM MEDIMMUNE AS MEDI0457 AND CHECKPOINT INHIBITOR COMBINATION TRIAL IN HEAD AND NECK SQUAMOUS CELL CANCER ADVANCES TO PHASE 2 Source text for Eikon: Further company coverage:

Select another date: